New insights into hypertension-associated erectile dysfunction

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 2, 2012, Pages 163-170

  Nunes, Kenia Pedrosa ^a   Labazi, Hicham ^a   Webb, R Clinton ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

antihypertensives; endothelial dysfunction; erectile dysfunction; hypertension

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; HYDROGEN SULFIDE; NEBIVOLOL; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE V INHIBITOR; VASODILATOR AGENT;

DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; MALE; MORPHOLOGICAL ADAPTATION; MUSCLE CONTRACTION; PRIORITY JOURNAL; REVIEW; VASCULAR SMOOTH MUSCLE;

ANTIHYPERTENSIVE AGENTS; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HUMANS; HYPERTENSION; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR;

EID: 84857043055     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835021bd     Document Type: Review

References (51)

1. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts male aging study. J Urology 2000; 163:460-463. (Pubitemid 30060493)
2. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84:50-56. (Pubitemid 29346774)
3. Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000; 164:1188-1191.
4. Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. J Am Med Assoc 2005; 294:2996-3002. (Pubitemid 41817661)
5. Costa C, Virag R. The endothelial-erectile dysfunction connection: An essential update. J Sex Med 2009; 6:2390-2404.
6. Shin D, Pregenzer G Jr., Gardin JM. Erectile dysfunction: A disease marker for cardiovascular disease. Cardiol Rev 2011; 19:5-11. Review discussing the evidences of erectile dysfunction as a marker for CVD.
7. Gratzke C, Angulo J, Chitaley K, et al. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med 2010; 7 (1 Pt 2):445-475. An overview about pathophysiological aspects in erectile dysfunction.
8. Billups KL. Erectile dysfunction as an early sign of cardiovascular disease. Int J Impot Res 2005; 17 (Suppl 1):S19-S24. (Pubitemid 43049373)
9. Chew KK, Finn J, Stuckey B, et al. Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: Findings from a linked-data study. J Sex Med 2010; 7 (1 Pt 1):192-202. Study evaluating evidences of erectile dysfunction as a strong predictive of subsequent atherosclerosis.
10. Nunes KP, Rigsby CS, Webb RC. RhoA/Rho-kinase and vascular diseases: What is the link? Cell Mol Life Sci 2010; 67:3823-3836. Review discussing the role of Rho-kinase plays in many vascular diseases, such as atherosclerosis, hypertension and erectile dysfunction.
11. Jin LM. Angiotensin II signaling and its implication in erectile dysfunction. J Sex Med 2009; 6 (Suppl 3):302-310.
12. Becker AJ, Uckert S, Stief CG, et al. Plasma levels of angiotensin II during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction. Urology 2001; 58:805-810.
13. Wynne BM, Chiao CW, Webb RC. Vascular smooth muscle cell signaling mechanisms for contraction to angiotensin II and endothelin-1. J Am Soc Hypertens 2009; 3:84-95.
14. Comiter CV, Sullivan MP, Yalla SV, Kifor I. Effect of angiotensin II on corpus cavernosum smooth muscle in relation to nitric oxide environment: In vitro studies in canines. Int J Impot Res 1997; 9:135-140. (Pubitemid 27427269)
15. Ertemi H, Mumtaz FH, Howie AJ, et al. Effect of angiotensin II and its receptor antagonists on human corpus cavernous contractility and oxidative stress: Modulation of nitric oxide mediated relaxation. J Urol 2011; 185:2414-2420. This study shows AngII peptide distribution in human penile tissue and the effect of its receptor antagonism on the nitric oxide/cGMP pathways.
16. Yang R, Yang B, Wen Y, et al. Losartan, an angiotensin type I receptor, restores erectile function by downregulation of cavernous renin-Angiotensin system in streptozocin-induced diabetic rats. J Sex Med 2009; 6:696-707.
17. Jin L, Lagoda G, Leite R, et al. NADPH oxidase activation: A mechanism of hypertension-Associated erectile dysfunction. J Sex Med 2008; 5:544-551. (Pubitemid 351337880)
18. Granchi S, Vannelli GB, Vignozzi L, et al. Expression and regulation of endothelin-1 and its receptors in human penile smooth muscle cells. Mol Hum Reprod 2002; 8:1053-1064. (Pubitemid 36032842)
19. Saenz de Tejada I, Carson MP, de las Morenas A, et al. Endothelin: Localization, synthesis, activity, and receptor types in human penile corpus cavernosum. Am J Physiol 1991; 261:H1078-H1085.
20. Holmquist F, Kirkeby HJ, Larsson B, et al. Functional effects, binding sites and immunolocalization of endothelin-1 in isolated penile tissues from man and rabbit. J Pharmacol Exp Ther 1992; 261:795-802.
21. Dai Y, Pollock DM, Lewis RL, et al. Receptor-specific influence of endothelin-1 in the erectile response of the rat. Am J Physiol Regul Integr Comp Physiol 2000; 279:R25-R30. (Pubitemid 30625412)
22. Carneiro FS, Giachini FR, Lima VV, et al. DOCA-salt treatment enhances responses to endothelin-1 in murine corpus cavernosum. Can J Physiol Pharmacol 2008; 86:320-328. (Pubitemid 351821124)
23. Wingard CJ, Husain S, Williams J, James S. RhoA-Rho kinase mediates synergistic ET-1 and phenylephrine contraction of rat corpus cavernosum. Am J Physiol Regul Integr Comp Physiol 2003; 285:R1145-R1152. (Pubitemid 37296367)
24. Ari G, Vardi Y, Hoffman A, Finberg JP. Possible role for endothelins in penile erection. Eur J Pharmacol 1996; 307:69-74. (Pubitemid 26226286)
25. Allahdadi KJ, Hannan JL, Tostes RC, Webb RC. Endothelin-1 induces contraction of female rat internal pudendal and clitoral arteries through ET(A) receptor and rho-kinase activation. J Sex Med 2010; 7:2096-2103.
26. Jiang R, Chen JH, Jin J, et al. Ultrastructural comparison of penile cavernous tissue between hypertensive and normotensive rats. Int J Impot Res 2005; 17:417-423. (Pubitemid 43093242)
27. Behr-Roussel D, Gorny D, Mevel K, et al. Erectile dysfunction: An early marker for hypertension? A longitudinal study in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2005; 288:R276-R283. (Pubitemid 40023940)
28. Toblli JE, Stella I, Inserra F, et al. Morphological changes in cavernous tissue in spontaneously hypertensive rats. Am J Hypertens 2000; 13:686-692. (Pubitemid 30459881)
29. Hale TM, Hannan JL, Carrier S, et al. Targeting vascular structure for the treatment of sexual dysfunction. J Sex Med 2009; 6 (Suppl 3):210-220.
30. Feletou M, Kohler R, Vanhoutte PM. Endothelium-derived vasoactive factors and hypertension: Possible roles in pathogenesis and as treatment targets. Curr Hypertens Rep 2010; 12:267-275.
31. Ushiyama M, Kuramochi T, Yagi S, Katayama S. Antioxidant treatment with alpha-tocopherol improves erectile function in hypertensive rats. Hypertens Res 2008; 31:1007-1013. (Pubitemid 351895045)
32. Ushiyama M, Morita T, Kuramochi T, et al. Erectile dysfunction in hypertensive rats results from impairment of the relaxation evoked by neurogenic carbon monoxide and nitric oxide. Hypertens Res 2004; 27:253-261. (Pubitemid 38594397)
33. Agarwal A, Nandipati KC, Sharma RK, et al. Role of oxidative stress in the pathophysiological mechanism of erectile dysfunction. J Androl 2006; 27:335-347. (Pubitemid 43667981)
34. Packer MA, Scarlett JL, Martin SW, Murphy MP. Induction of the mitochondrial permeability transition by peroxynitrite. Biochem Soc Trans 1997; 25:909-914. (Pubitemid 27416962)
35. Khan MA, Thompson CS, Mumtaz FH, et al. The effect of nitric oxide and peroxynitrite on rabbit cavernosal smooth muscle relaxation. World J Urol 2001; 19:220-224.
36. Yang G, Wu L, Jiang B, et al. H2S as a physiologic vasorelaxant: Hypertension in mice with deletion of cystathionine gamma-lyase. Science 2008; 322:587-590.
37. Srilatha B, Adaikan PG, Li L, Moore PK. Hydrogen sulphide: A novel endogenous gasotransmitter facilitates erectile function. J Sex Med 2007; 4:1304-1311. (Pubitemid 47337674)
38. d'Emmanuele di Villa Bianca R, Sorrentino R, Maffia P, et al. Hydrogen sulfide as a mediator of human corpus cavernosum smooth-muscle relaxation. Proc Natl Acad Sci U S A 2009; 106:4513-4518.
39. Srilatha B, Adaikan PG, Moore PK. Possible role for the novel gasotransmitter hydrogen sulphide in erectile dysfunction: A pilot study. Eur J Pharmacol 2006; 535 (1-3):280-282.
40. Liaw RL, Srilatha B, Adaikan PG. Effects of hydrogen sulfide on erectile function and its possible mechanism(s) of action. J Sex Med 2011; 8:1853-1864. This review describes the hydrogen sulfide effect on erectile function and possible mechanisms through which hydrogen sulfide may exert its pro-erectile actions.
41. d'Emmanuele di Villa Bianca R, Sorrentino R, Mirone V, Cirino G. Hydrogen sulfide and erectile function: A novel therapeutic target. Nat Rev Urol 2011; 8:286-289. This review describes the physiological role of hydrogen sulfide in the control of penile tone and proposes that drugs that can stimulate hydrogen sulfide signaling may be used as therapeutic approach to treat erectile dysfunction.
42. Vital signs: Prevalence, treatment, and control of hypertension: United States, 1999-2002 and 2005-2008. Morb Mortal Wkly Rep 2011; 60:103-108.
43. Papatsoris AG, Korantzopoulos PG. Hypertension, antihypertensive therapy, and erectile dysfunction. Angiology 2006; 57:47-52.
44. Doumas M, Douma S. The effect of antihypertensive drugs on erectile function: A proposed management algorithm. J Clin Hypertens (Greenwich) 2006; 8:359-364.
45. De Caterina AR, Leone AM. The role of beta-blockers as first-line therapy in hypertension. Curr Atheroscler Rep 2011; 13:147-153. Review reporting available evidence supporting the efficacy of b-blockers in reducing BP and cardiovascular morbidity.
46. Cordero A, Bertomeu-Martinez V, Mazon P, et al. Erectile dysfunction in highrisk hypertensive patients treated with beta-blockade agents. Cardiovasc Ther 2010; 28:15-22.
47. Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens (Greenwich) 2011; 13:687-689.
48. Israili ZH, Hernandez-Hernandez R, Valasco M. The future of antihypertensive treatment. Am J Ther 2007; 14:121-134. (Pubitemid 46597649)
49. Ritchie R, Sullivan M. Endothelins and erectile dysfunction. Pharmacol Res 2011; 63:496-501. Review discussing the role of endothelin in the penile tissue and the cause of erectile dysfunction, and discussing recent findings about ET antagonism effect on erectile dysfunction.
50. Montani D, Chaumais MC, Savale L, et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009; 26:813-825.
51. Angulo J, Wright HM, Cuevas P, et al. Nebivolol dilates human penile arteries and reverses erectile dysfunction in diabetic rats through enhancement of nitric oxide signaling. J Sex Med 2010; 7:2681-2697. This article provides evidence that the new generation of b-blocker, nebivolol, may have positive effects on erectile function by activation of the nitric oxide/cGMP pathway.